Cost-effectiveness Analysis of CYP2C19 Genotype-guided Antiplatelet Therapy for Patients with Acute Minor Ischemic Stroke and High-risk Transient Ischemic Attack in China.
Zhuolin ZhangYuwen BaoYajie GuMengdie ZhangXin LiPublished in: British journal of clinical pharmacology (2023)
CYP2C19 genotype-guided antiplatelet therapy, cilostazol, and ticagrelor as an alternative to clopidogrel, appeared to be more cost-effective than conventional antiplatelet therapy for acute minor ischemic stroke and high-risk transient ischemic attack patients over 30 years in China.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- cerebral ischemia
- end stage renal disease
- atrial fibrillation
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- newly diagnosed
- ejection fraction
- coronary artery disease
- chronic kidney disease
- liver failure
- ischemia reperfusion injury
- peritoneal dialysis
- oxidative stress
- respiratory failure
- patient reported outcomes
- acute respiratory distress syndrome
- hepatitis b virus